THE ROLE OF OXIDATIVE DAMAGE IN MITOCHONDRIA DURING AGING: A REVIEW

Hai Huang, and Kenneth G Manton

Center for Demographic Studies, Duke University, 2117 Campus Drive Box 90408, Durham, NC 27708

TABLE OF CONTENTS

- 1. Abstract
- 2. Introduction
- 3. The chemistry of reactive oxygen species (ROS)
- 4. Normal functions of ROS
- 5. Classes of macromolecules undergoing oxidative damage
- 6. Mitochondria as the major sources and targets of ROS
 - 6.1. Structure of mitochondria
 - 6.2. Mitochondrial functions
 - 6.3. Mitochondrial DNA
 - 6.4. mtDNA mutations
 - 6.5. Role of mitochondria in telomere shortening
 - 6.6. Role of mitochondria in apoptosis: relevance to aging
 - 6.7. Functional decline of Mitochondria with aging
- 7. The role of ROS in geriatric disorders
 - 7.1. Alzheimer's disease (AD)
 - 7.2. Parkinson's and other neurogenerative diseases
- 8. Evidence for or against oxidative damage as a major mechanism of aging
 - 8.1. Drosophila studies
 - 8.2. C. Elegans studies
 - 8.3. Mouse studies
- 9. Conclusions
- 10. Acknowledgements
- 11. References

1. ABSTRACT

Aging is a complex process (or series of processes). Recent evidence suggests that several of its most important mechanisms are linked by means of cellular damage caused by reactive oxygen species (ROS). Oxidative damage may be a major factor in the loss of physiological functions that occur in degenerative diseases and aging. This is because, in aerobic organisms, the mitochondrial electron transport chain plays an important role in energy production and is a significant source of ROS that damage DNA, RNA, and proteins in cells. While oxidative events in other cell organelles are likely to contribute to the pathobiology of aging, this review highlights alterations in mitochondrial function that, due to accumulated oxidative damage, occur with age.

2. INTRODUCTION

Oxidative damage is hypothesized to be one cause of aging in metazoans (1-7). Oxidatively damaged macromolecules accumulate with age in every organism examined; thus, oxidative damage is implicated in many human age-related diseases. We will review studies of oxidative damage in mitochondria during aging and arguments for or against oxidative damage as a major mechanism of aging (7).

3. THE CHEMISTRY OF REACTIVE OXYGEN SPECIES

ROS are produced as a byproduct of normal cellular metabolism. Aerobic organisms are constantly subjected to ROS, which include:

I. Species derived from reduction of molecular oxygen:

- 1. Superoxide
- 2. Hydrogen peroxide
- 3. Hydroxyl radical

II. Species derived from reaction of carbon-centered radicals with molecular oxygen:

- 1. Peroxyl radicals
- 2. Alkoxyl radicals
- 3. Organic hydroperoxides

III. Other oxidants that can result in free radical formation:

- 1. Hypochlorous acid
- 2. Peroxynitrite
- 3. Singlet oxygen

A major ROS produced by the cell is superoxide, which is converted by SOD to hydrogen peroxide (H_2O_2) .

Catalase and superoxide dismutase (SOD) are enzymes defending against ROS in all cells; Catalase converts H_2O_2 to molecular oxygen and water, however their defense is not always completely effective.

SOD exists in two major forms in the eukaryotic cell: Cu,ZnSOD in cytoplasm and MnSOD in mitochondria, which are thought to be the primary cellular source of ROS and which accumulate oxidative damage. Thus, MnSOD may be an important defense against oxidative damage. In mice MnSOD appears to be more critical because its mutations have more severe consequences than Cu,ZnSOD mutations (8,5).

Ozone, nitric oxide, and nitrogen dioxide are also ROS from exogenous sources. The latter two are also produced endogenously (9). Possibly the most prolific source of ROS, particularly superoxide and hydrogen peroxide, is leakage from the mitochondrial electron transport chain (10). Superoxide is formed in various autoxidation reactions and by enzymes such as peroxidases, cytochrome P450, and xanthine oxidase (11). By means of the respiratory burst oxidase, as a defense mechanism against infectious agents, phagocytes also produce ROS (12-14).

Some experimental and epidemiological studies suggest that administration of antioxidants may prevent development of age-associated disorders such as cancer (15) or cardiovascular and neurodegenerative diseases (16,17) (e.g., Parkinson's and Alzheimer's disease (18,19). But the Beta-Carotine and Retinal Efficacy Trial (CARET study by Omenn et al., [20]) showed that after an average of four years of supplementation, the combination of betacarotene and vitamin A had no benefit and may have had an adverse effect - on the incidence of lung cancer and the risk of death from lung cancer, cardiovascular disease, and any other cause in smokers and workers exposed to asbestos. Three other studies (Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study [ATBC] [21]), Physicians' Health Study [22] and the Linxian Study in China [23]), examining the effects of supplementary vitamin A and beta-carotene, suggest hypotheses for the lack of effect.

In the CARET and ATBC studies, the study populations were at high risk. In these studies the administration of vitamin A appeared to have an adverse effect on populations who presumably had already suffered cellular damage leading to morbidity and death. In the Physicians study, where there was a mix of high and low risk groups (smokers and non-smokers), there was no elevation (RR=1.01) of risk which could plausibly be the average of an elevated risk in smokers and a lower risk in supplemented non-smokers. In the Chinese study a benefit (RR=0.91) was discovered in a population with a presumed deficiency of vitamin A. Consistent with this is the negative correlation of high cancer risks and baseline vitamin A serum levels in the CARET study.

Two basic explanations are suggested. First, is that once significant oxidative damage is incurred in high

risk groups, vitamin A will not reverse it and, as a potent hormonal factor in cell growth and differentiation, could even promote late stages in a multi stage model of carcinogenesis. Second, the redox relations of vitamins A, C, and E are complex and might be distributed by supersupplementation of vitamin A. Thus the CARET study may reflect more on the use of vitamin A as a "treatment" rather than as a preventative anti-oxidant. A conclusive study would be to start supplementation before starting toxin exposure, (e.g., smoking).

4. NORMAL FUNCTIONS OF ROS

ROS formation takes place during normal physiological functioning (24,25). Under aerobic conditions in living cells, superoxide anions and hydrogen peroxide are produced and converted into hydroxyl radicals by the iron-catalyzed Fenton reaction. Excessive ROS production may overwhelm the antioxidant capacity of cells (such as intracellular nonprotein sulfhydryls [NPSH]) to modulate cytotoxicity, thereby initiating a pathogenic cascade of events (26). This is exemplified in mitochondria by interactions of free radicals with transition metal centers. Gerschman *et al* (27) recognized: 1.) ROS are the common mechanism of oxygen and radiation toxicity; 2.) an increase in prooxidants, or a decrease in antioxidants, will lead to cell damage; and 3.) oxygen toxicity is a continuous phenomenon.

5. CLASSES OF MACROMOLECULES UNDERGOING OXIDATIVE DAMAGE

Accumulation of molecular oxidative damage may be important in the senescence-related decline of the physiological fitness of organisms (28,29). Such damage is a random, rather than a controlled, process (30-32). Old animals have increased mitochondrial production of superoxide and hydrogen peroxide (33,34). Many studies demonstrate the sensitivity of mitochondrial protein, lipids, and DNA to oxidative stress (35-38).

Accumulation of proteins damaged by oxidative stress depends on tissue, cell, and protein type (39, 2, 40,32). The adenine nucleotide translocase (ANT) protein shows strong carbonylation during normal aging because it: a.) contains readily oxidized arginine, proline, and lysine residues and b.) is associated with cardiolipin containing unsaturated fatty acids (32). Accumulation of oxidized dysfunctional protein in carbonyl groups could lead to inter- and intra-molecular cross-links with other amino groups and, therefore, to loss of biochemical and physiological function. Age-related accumulation of protein oxidation products in mitochondria may disrupt the efficiency of energy production, thereby increasing ROS production (2).

Head *et al* (41), in a canine model, showed an increase in lipid peroxidation with age. Increasing oxidative damage to lipids was found in the brain and serum, but not in cerebrospinal fluid (CSF). The correlation of malondialdehyde (MDA) levels in brain and serum suggests that damage occurs both centrally and

systemically. MDA levels may reflect not only the extent of lipid peroxidation, but also the oxidative susceptibility of high- and low-density lipoproteins in serum (42). Agedependent increases in MDA levels may be due to increases in serum protein (43). MDA can cross-link protein side-chains, slow protein degradation, and reduce protein turnover in rats and humans (44).

Mechanisms underlying the age-dependent increase in serum MDA may be linked to oxidative damage - which, in DNA, accumulates over the life of a cell (45,46). Generation of DNA strand breaks is necessary to trigger the p53-dependent cell cycle pathway (47), which mediates inhibition of proliferation and apoptosis with features observed in replicatively senescent normal diploid somatic cells (48). Whether or not strand breaks occur depends on stabilization of the p53 tumor suppressor gene product and induction of downstream mediators (49). There are conflicting data on the relation of oxidative stress and the type of proliferative senescence described by Hayflick (50,51). Several experiments demonstrated oxidative stress inhibits cell proliferation; others indicated inhibition of proliferation mediated by hyperoxia was reversible (52,53).

During oxidative damage aging, to macromolecules increases exponentially in a variety of tissues in different species (54). That such damage causes functional loss was found by in vitro models (55). Stadtman (56) demonstrated that oxidative damage to proteins causes loss of catalytic and structural integrity; altered proteins are preferentially hydrolyzed. Protein and lipid oxidation products may form cross-linked, undegradable products such as lipofuscin (57). Studies (58;59) indicate that oxidative damage to proteins is selective, implying that some, but not all, catalyzed reactions are impaired in aging. Specificity of protein damage provides a link between ROS and senescence-associated functional alterations (e.g., agerelated carbonylation of mitochondrial aconitase and ANT in flies is associated with loss of protein activity [59]).

6. MITOCHONDRIA AS MAJOR SOURCES AND TARGETS OF ROS

Mitochondria are an important link between accumulation of oxidative damage caused by ROS and alterations in function associated with aging (60). Oxidative damage in mitochondria is the leading candidate for a unitary mechanism of aging in aerobic organisms (3). The mitochondrial theory of aging, a variant of the free radical theory of aging, suggests that accumulation of damage to mitochondria, mitochondrial DNA (mtDNA), and RNA leads to aging in both humans and animals (61-65). Because approximately 90% of cellular oxygen is consumed in mitochondria is not reduced to water, mitochondria may be the major intracellular contributor to superoxide (O_2^{-}) generation - and perhaps oxidative stress in general (34)

6.1. Structure of mitochondria

Mitochondria are the main sources of energy in the cell. They contain their own mtDNA, a small 16.5 kb

circular molecule in humans coding for 13 polypeptides, 22 tRNAs, and 2 rRNAs - all of which are components of the respiratory-chain/oxidative phosphorylation system (66). Mitochondria have four structural compartments: matrix, inner membrane, intermembrane space, and outer membrane. In the inner membrane there are protein systems, such as the electron transfer chain complexes (20⁺ discrete electron carriers and an unspecified number of "structural" proteins, all of which are organized into four multi-protein complexes [I-IV]) and the "fifth" complex, F_1F_o -ATP synthase, [67]).

Optimal oxidative phosphorylation requires energytransducing membranes to have: a.) low proton conductance and b.) exchange carriers allowing metabolites to permeate while maintaining osmotic stability. Nicholls (68) suggested that, in the mitochondrial inner membrane, the high proportion of protein (50% integral protein, 25% peripheral protein, and 25% lipid) results in close packing of proteins. Recent x-ray studies indicate that much of the protein mass is in water outside the lipid bilayer so the mitochondrial bilayer may be more substantial than Nicholls suggests (69).

6.2. Mitochondrial functions

Mitochondrial functions include ATP production, heme and cholesterol biosynthesis, and cellular calcium regulation (70). Although these functions are the most important intracellular sources of oxidants (71,72), it is uncertain how much Q_2^- they form (73). The main sites where O_2^- is generated are the ubiquinone pool and nicotinamide adenine dinucleotide (NADH) dehydrogenase (Complex I). Electrons are transferred, individually, to form ubisemiquinone, which reacts with oxygen to form O_2^- . Mitochondrial macromolecules and mitochondria that are isolated from old animals may produce more H_2O_2 than younger animals (72-74). These oxidants (O_2^- and H_2O_2).damage cellular macromolecues, including DNA, protein and lipid. Accumulation of such damage may contribute to aging and age-associated degenerative diseases.

6.3. Mitochondrial DNA

Mitochondrial DNA (mtDNA) is located in the matrix and is attached to the inner membrane. mtDNA lacks introns, histones, and other DNA proteins and has less complete repair mechanisms than nuclear DNA (nDNA) (75-76). This makes mtDNA prone to oxidative damage. Damage in mtDNA is more extensive, rapid and persistent than damage in nDNA (31). ROS-promoted damage to mtDNA includes fragmentation and deletions. A marker for damage, 8-hydroxy-deoxyguanosine (8-OHDG) (77), increases with age and degenerative diseases. In vitro oxidative stress, as occurs during mitochondrial lipid peroxidation or during the transition, is accompanied by mtDNA fragmentation and increases in 8-OHDG. Because mtDNA encodes proteins involved in electron transport and oxidative phosphorylation, oxidative damage may lead to respiration and phosphorylation deficiencies (74).

6.4. MtDNA mutations

Since the sequencing of human mtDNA in 1981 (78), a number of mutations have been described and linked

to a heterogeneous class of age-related disorders (79). The incidence and abundance of mutant mtDNAs increase with age, particularly in tissues with high energy demands (80-88). A variety of point mutations are detectable (89). Khrapko *et al* (90) found that colon, lung, muscle, and tumors derived from these tissues share many mitochondrial "hotspot" point mutations. Tissue-specific characteristic mtDNA was discovered in Attardi's lab at CalTech (91). The levels of 8-OHDG mtDNA adducts and deletions increase exponentially with age. (92-96). In human skeletal muscle, fibers lacking cytochrome c oxidase (complex IV) activity accumulate with age (97,98).

Certain control region (CR) mtDNA mutations also accumulate with age (99). Mixtures of mutant and normal CR mtDNAs (heteroplasmy) have been reported in human brain (100), hair (101) and cancer (102,103) cells. Mitochondrial oxidative phosphorylation (OXPHOS) enzyme activities decline with age in human and primate muscle (86,104,105), liver (106), and brain (107) tissue. Cytochrome c oxidase (COX)-deficient muscle fibers accumulate with age in heart and skeletal muscles (108,109). COX-negative regions contain clonal expansions of individual mtDNA rearrangements (110). This increase correlates with accumulation of mtDNA mutations, including deletions (80,82-85,92,110-126) and base substitutions (123-126)

mtDNA damage is high in tissues prone to agerelated dysfunction. Basal ganglia accumulate the most mtDNA damage, followed by various cortical regions. The cerebellum remains relatively free of mtDNA damage throughout life (127,119). This suggests that accumulation of mtDNA mutations may be important in the age-related decline of somatic tissues (111,128,129). As mutations accumulate, they exacerbate inherited OXPHOS defects until combined defects result in energetic failures (129).

A few hundred to a few thousand mtDNA molecules are present in an individual cell. Production of these molecules is not correlated with cell cycle parameters. During mitosis (or meiosis), mitochondria are randomly distributed to daughter cells. The existence of multiple DNA molecules, all susceptible to mutation, leads to heteroplasmy (130). mtDNA heteroplasmy is found in numerous types of animals (131). Phenotypic manifestations of mtDNA mutations are dependent on the levels of heteroplasmic mutant mtDNA in a cell, tissue, or organ (79, 132-137).

6.5. Role of mitochondria in telomere shortening

Human telomeres are specialized chromosomal end structures composed of TTAGGG repeats. These telomeres protect chromosomes from degradation, fusion and recombination (138). Immortal eukaryotic cells, including transformed human cells, use telomerase, an enzyme that elongates telomeres, to overcome incomplete replication. However, telomerase has not been detected in normal somatic cells, which lose telomere length as they replicate (139).

In telomere the TG strand is longer than its complement, leaving a region of single-stranded DNA of

up to a few hundred nucleotides at the 3' end. In mammals, the single-stranded end is sequestered in a "T loop" (140), is folded back, and paired with its complement in the double-stranded portion of the telomere. Looped DNA is bound by proteins TRF1 and TRF2. T loops may protect the 3' ends of chromosomes, making them inaccessible to nuclease and enzymes that repair double-strand breaks (141). Data suggest that the G-rich strand is more vulnerable to oxidative damage (142). Opening the telomeric loop and exposing the single-stranded, G-rich overhang might signal arrest of the cell cycle. Short telomere length, single-strand breaks, low levels of loopstabilizing proteins, or other factors may trigger opening of the loop (143,144).

6.6. Role of mitochondria in apoptosis: Relevance to aging

Mitochondria are central to the life and death of eukaryotic cells (145-152). Mitochondria contain and release apoptotic proteins (e.g., cytochrome c and apoptosis-inducing factor [153]). The mitochondrial permeability transition (PT) pore is critical in apoptosis. Opening of the PT pore releases cytochrome c and apoptosis-inducing factor (AIF) into cytosol (154). Mitochondrial oxidative stress occurs early in apoptosis prior to DNA fragmentation - and may cause PT pore opening. Esteve (155) found decreases in mitochondrial membrane potential (and an increase in peroxide content) in apoptotic fibroblasts. Experiments show that change in mitochondrial activity is common in apoptosis (156-158). ROS-induced apoptosis may remove mitochondria when ROS production exceeds scavenging capacity (159).

Age-related alterations in the mitochondrial pathway of apoptosis can affect tissue function. These alterations can arise from oxidative damage to mitochondria. Common features of apoptotic cells and cells from old animals include increased mitochondrial peroxide production, oxidation of glutathione, and oxidation of mtDNA (160). mtDNA and respiration are not essential for apoptosis (161,162). However, the absence or impaired function of mtDNA can influence the rate of this process probably by regulating ROS production (163). Therefore, it appears that the relation of aging and apoptosis is not established.

6.7. Functional decline of mitochondria with aging

With age, mitochondrial function declines and mtDNA mutations increase. Cell energy deficits (caused by declines in mitochondrial function) can impair cell activities and compromise adaptation to physiological stress (164). Age-related impairment in respiratory enzymes decreases ATP synthesis and enhances ROS production by increased electron leakage in the respiratory chain. Human mtDNA is susceptible to oxidative damage and mutation when exposed to high levels of ROS (64).

Aging is associated with declines in the capacity of various cell types, including neurons, to respond to metabolic stress due to impairment of mitochondrial function. Although some neurodegenerative diseases are associated with mitochondrial dysfunction, it is not clear if changes are due to normal aging or to exposure to pathophysiologic agents (67).

Mitochondrial ROS generation has been studied in animal models of neuronal disease (165). De la Asuncion *et al* (166) found mitochondrial glutathione markedly oxidized with aging in rats and mice. The oxidized-toreduced-glutathione ratio increases with age in the liver, kidney, and brain. In the liver, glutathione disulfide (GSSG) as a percent of glutathione (GSH) changed from 0.77 + -0.19% (n =5) in young rats to 2.47 + -1.25% (n=5) in old ones. In the brain and kidney, values for old rats were higher than those for young rats. Oral antioxidants protected against glutathione oxidation and mtDNA damage in rats and mice.

Sohal (167) argues that accrual of molecular oxidative damage as a mechanism governing the rate of aging, is supported by: () life span of cold blooded animals and mammals with unstable basal metabolic rate (BMR) being extended and oxidative damage attenuated by a decrease in metabolic rate (Experimental life span extensions are accompanied by reduced oxidative damage. Both activity and regimen might affect life span. For example, elimination of flying prolongs the life span of flies by 3-fold and decreases accumulation of protein and DNA oxidative damage [168,169]. Regimens that extend life span of poikilotherms decrease metabolic rates and accumulation of oxidative damage [170]).; (ii) single gene mutations in Drosophila and C. elegans that extend life span slow physiological activities, albeit via different mechanisms, decreasing oxidative damage; and (iii) caloric restriction decreases body temperature and oxidative damage. He indicates that studies of transgenic over expression of antioxidant enzymes are supportive but ambiguous.

In rodents, life span is extended if caloric intake is decreased from the level of ad libitum fed animals. The temperature of calorically restricted animals is daily transiently lowered by as much as 4° C in rats and 13° C in mice, indicating that a BMR is responsive to caloric intake (171,172). Stadtman (173) found that protein carbonyls increase with age in insects with steady state concentration inversely related to life expectancy. This was confirmed in mammals. Macromolecular oxidative damage rates of mitochondrial ROS increase with age and are inversely related to species mean life span (MLS) (174).

7. THE ROLE OF ROS IN GERIATRIC DISORDERS

ROS are involved in many diseases of the elderly, including Alzheimer's disease (AD) and Parkinson's disease(PD), as well as conditions affecting vision, such as cataracts and macular degeneration (175). Neurodegenerative diseases have been linked to mutations in mtDNA and nDNA. Genetic and phenotypic variability of mitochondrial diseases is due to the number of mitochondrial genes involved and the cell pathways and functions in which mitochondria play a role.

Oxidative modification of proteins is important in aging and age-related neurodegenerative disorders (176, 2).

Modification of amino acid side chains in proteins can lead to diminished function (176,2,177). Degradation of oxidized proteins by proteinases is possible, but oxidatively induced, proteinase-resistant, protein cross-linking can occur preventing removal (178,179).

7.1. Alzheimer's disease (AD)

Oxidative damage may play a critical role in AD neuropathology (180). Friede (181) noted alterations of oxidative metabolism in AD. This might precede and drive amyloid deposition in brains of affected subjects. Extensive evidence suggests that lipid peroxidation is important in AD. Indices of lipid peroxidation in AD include TBARS, phospholipid composition, levels of alpha- and betaunsaturated aldehydes, activities of enzymes that clear lipid peroxidation products, and concentrations of isoprostanes (180,176).

The most abundant oxidized DNA base product from hydroxyl radical attack is 8-OHDG. mtDNA had a threefold increase of 8-OHDG in the AD parietal cortex compared with controls. A small, but noticeable, increase in 8-OHDG in nDNA in AD cases, compared to controls, was reported (182). Results, confirmed using gas chromatography/mass spectrometry (183), were expanded to frontal, parietal, and temporal lobes (184). Immunocytochemical detection of 8-OHDG and 8-hydroxyguanosine showed increased DNA and RNA oxidation is limited to vulnerable neurons in AD (185,186). mtDNA abnormalities in AD were confirmed by *in situ* hybridization studies (187).

The AD brain shows higher levels of oxidative damage to proteins (188) and lipids (189). This may be due to the deposition and accumulation of (A β) protein in senile plaques (190). Amyloid precursor protein (APP), from which A β is proteolytically cleaved (191), is vulnerable to oxidative damage and exposing APP to metabolic stress favors production of amyloidogenic fragments (192,193).

Epidemiological studies show a large reduction in AD risk due to consumption of Non Steroidal Anti-Inflammatory Drugs (NSAIDs) -- especially ibuprofen (194). Ibuprofen may reduce the risk of AD — not only through its anti-inflammatory properties but also due to direct effects on amyloid proteins. Other drugs showing promise in controlling AD are statins (possibly because of anti-inflammatory properties) and the effects of nicotine metabolites on amyloid proteins (195).

7.2. Parkinson's and other neurognerative diseases

Mitochondrial dysfunction occurs in Parkinson's disease (PD). Humans exposed to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) developed PD (196,197). MPTP is converted to 1-methyl-4-phenylpyridine (MPP+) by monoamine oxidase in glial cells (198). MPP+ is taken up by cells possessing dopamine reuptake sites and concentrated in negatively charged mitochondrial matrices (199,200). Inside mitochondria, MPP+ inhibits Complex I (201) causing degeneration of catecholaminergic neurons in the *substantia nigra* and *locus ceruleus* (196,197,202,203).

Evidence of mitochondrial dysfunction also exists for other neurodegenerative diseases (e.g., degenerating and nondegenerating tissues of Amyotrophic lateral sclerosis (ALS) subjects [204] in progressive supranuclear palsy and multisystem atrophy [205-208] and Huntington's disease. Treatment of mitochondrial dysfunction is hampered by the difficulty of delivering bioactive molecules in vivo. Vitamin E has had only a modest effect on AD in epidemiologic studies. Smith et al (209) developed a strategy for targeting bioactive molecules to mitochondria by attaching them to the lipophilic triphenylphosphonium cation through an alkyl linker. These molecules rapidly permeate lipid bilayers and, because of the large mitochondrial membrane potential (negative inside), accumulate several hundredfold in isolated mitochondria and in mitochondria in cultured cells. For example, a triphenylphosphonium cation was coupled to coenzyme Q or vitamin E derivatives. Significant doses of these compounds could be fed safely to mice over long periods, coming to steady-state distributions within the heart, brain, liver, and muscle. Therefore, mitochondria-targeted bioactive molecules can be administered orally, leading to accumulation at potentially therapeutic concentrations in tissues affected by mitochondrial dysfunction. Targeting bioactive molecules to mitochondria can be adapted to any neutral, bioactive molecule. This complements approaches to target DNA and molecules related to mitochondria (210-212).

8. EVIDENCE FOR OR AGAINST OXIDATIVE DAMAGE AS A MAJOR MECHANISM OF AGING

The SOD mimetic EUK-8 is a research tool for investigating mechanisms of aging. It was reported to have extended lifespan in *C. elegans* (213). However, Keaney and Gems, (214), in five trials administering EUK-8 in liquid culture with *E. coli*, and two trials using defined liquid medium, found no increase in lifespan, but a dose-dependent reduction of lifespan and fertility. Extension of *C. elegans* lifespan by EUK-8 may occur only under specific culture conditions.

8.1. Drosophila studies

To test models of oxidative aging, creation of transgenic organisms complements traditional genetics. *Drosophila melanogaster* is a popular model because of transgenic and other genetic and molecular tools available, its short life span (1–2 months), and ease of culture (215-217).

In Drosophila engineered to overexpress MnSOD, Tower (218) used five approaches: two single component systems (transgenes with native [normal] promoters and transgenes with heterologous promoters) and three binary systems ("GAL4/UAS", "FLP-out", and "tet-on"). He concluded that over-expression of Cu,ZnSOD and MnSOD genes increases life span.

Several studies tested the oxidative stress hypothesis to determine if overexpression of antioxidative enzymes, either alone or in combination, increased life span in transgenic *Drosophila* (174). Three groups reported that overexpression of Cu,ZnSOD increased life span (219).

Orr and Sohal (220) reported that life span extension in *Drosophila* studies involving P element-

mediated introduction of genomic fragments bearing the coding sequence and attendant regulatory sequences including promoter, intron and 3' flanking sequences of Cu,ZnSOD and catalase . No survival effects were found in transgenic flies possessing a single extra copy of either Cu,ZnSOD (221), or catalase (222). The life span of flies with extra copies of both Cu,ZnSOD and catalase increased by up to 34% over controls bearing two vector-only insertions. This was accompanied by increased physical activity, reduction in oxidative damage, and increased metabolism as measured by oxygen consumption. Because cis-regulatory sequences are present, overexpression of antioxidative genes is likely to follow normal physiological expression. Since P element insertion is a quasi-random process, expression can be impacted by regulatory regions near the insertion site — or the P element insertion can act to alter gene expression at (or near) the integration site. "Position effects" can impact longevity so it is important to use multiple lines (219).

Sun and Tower (223) used the FLP-out binary transgenic system, which yields transgene expression in adults in all tissues. One element of this system is the FLP recombinase transgene control led by a heat shock promoter. The second is the target gene under control of a constitutive promoter (Actin 5C), interrupted by a FLP recognition target (FRT) bounded sequence preventing expression. FRTs are target sequences for FLP recombinase. Consequently heat shock may liberate FRTdefined elements, permitting expression of the target gene. Advantages of this system are, a.) expression of the Cu,ZnSOD gene can be delayed until the adult phase avoiding negative consequences of over-expression on redox regulation during development and, b.) control is represented by genetically identical flies not subjected to heat shock. Since the two elements of this system are inserted by P element-transformation, position effects can affect expression as well as expression of neighboring genes, which can affect longevity.

The amount of MnSOD enzyme overexpression varied between six independent transgenic lines, with increases of up to 75%. Life span increased in proportion to increases in MnSOD enzyme. MLS increased up to 33%. Maximum life span, as measured by time to 90% mortality, increased by as much as 37%. Therefore, adult Drosophila life span is limited by MnSOD activity, analogous to results for Cu,ZnSOD (223,224). Both Cu,ZnSOD and MnSOD increased mean and maximum life span with no detectable negative effect on metabolic activity. Overexpression of catalase and MnSOD did not increase life span, consistent with catalase being found in excess in adult flies (223).

Sun and Tower (223) found, in most cases, no life span extension in female flies. With the exception of the SOD^{3A1} line, extensions in male flies were observed in short-lived lines (mean life spans <40 days). In a third experiment, male life span increases of 48% and 14% were noted, where control mean life spans were 25 and 36 days. The genetic component impacted life span increases only of male flies. Their graph of life span extension vs. control life span reveals a negative correlation, suggesting that

Cu,ZnSOD has beneficial effects only in a compromised genetic background. A rescue effect is notable, but its relevance to aging uncertain.

Parkes *et al* (224), to determine the consequences of SOD1 overexpression in motorneurons on normal longevity, generated transgenic *Drosophila* expressing human SOD1. Using the GAL4/UAS system, they demonstrated that overexpression of SOD1 motorneurons extends lifespan by up to 40% and rescues the lifespan of a short-lived SOD null mutant. This suggests that SOD activity in motorneurons is important to aging and longevity in *Drosophila*. Life span increase was sufficiently large, relative to its genetic variation, to be convincing.

However, Tower (218) indicated that increased longevity is not associated with decreased metabolism as assayed by O_2 consumption; therefore, both life span and metabolic potential might be increased. The pattern of expression produced by the D42-Gal4 "driver" was: broad during embryogenesis; in motorneurons, interneurons, some peripheral glial cells, and low level in fat body in larvae; a small number of cells within the central brain; and in motorneurons within the ventral ganglia in adults.

Expression in any or all of these tissues and stages could extend life span. Since, in adults, aging occurs primarily in motor neurons, these neurons are likely an important site of transgene action (218).

In *Drosophila*, overexpression of Cu,ZnSOD and catalase (but not of either alone) increased mean lifespan by 33% (220). This indicates that control of ROS and a need to balance SOD and catalase (225) are important for longevity. The balance differs over cell types because overexpression of human SOD1, without additional catalase in *Drosophila* motor neurons, extends lifespan (224).

8.2. C. elegans studies

The dauer is an alternative larval stage in *C*. *elegans* which allows animals to survive low food availability. Well-fed worms live three weeks. Dauer larvae can live for two months without affecting post-dauer lifespan (226). Mutations in *daf-2* and *age-1*, produce a dauer constitutive (Daf-C) phenotype and in *clk-1* mutations, which are believed to slow metabolism and markedly increase lifespan (227).

Taub *et al* (228) no longer have confidence in observations associating a reduction in *C. elegans* adult lifespan with a mutation in the catalase gene *ctl-1*. They confirmed that *C elegans* has multiple catalase genes and that the original strain, TU1061, had decreased transcription of *ctl-1* messenger RNA. They found several errors - one identifying a single nucleotide deletion as the defect in the *ctl-1* mutation and others in the identification of strains carrying mutations in multiple genes. They did not see the expected reduction in *ctl-1* mRNA in other strains. Longevity results obtained with these strains are therefore meaningless.

A handful of genes affect *C. elegans* lifespan through pathways downstream or parallel to the insulin

signaling pathway. The feeding-defective *eat* mutants live slightly longer in a *daf-16*-independent manner. *eat* mutations might extend lifespan through a mechanism resembling caloric restriction in mammals (229). *clk* (biological timing abnormality) mutations also extend lifespan, though not as much as mutations in *daf-2* pathway genes, and slow physiological processes (230). *clk-1* encodes a protein in coenzyme Q synthesis, implicating mitochondria in lifespan determination (231,232). *clk-2* encodes a protein in DNA repair and telomere maintenance (233-235).

Lee *et al* (236) used 5,690 genes in an RNAi screen to identify genes that, when inactivated, extend lifespan. A number of genes essential for mitochondrial function affected *C. elegans* lifespan. In a screen for increased lifespan, they found a probable null mutation in a mitochondrial leucyl-tRNA synthetase gene (*lrs-2*) increased lifespan.

Long-lived worms with impaired mitochondria had lower ATP content and oxygen consumption, but different responses to ROS and other stress. Thus, the longer lifespan of *C. elegans* with compromised mitochrondria cannot be due simply to lower ROS production, suggesting a more complex coupling of metabolism and longevity.

8.3. Mouse studies

Van Remmen (235) found that oxidative damage occurs during aging of SOD2 knockout heterozygotes. Heart mitochondria from heterozygous ($Sod2^{-/+}$) knockout mice had 50% less MnSOD. The decrease was associated with increased oxidative damage (reduced activity of iron-sulfur proteins sensitive to oxygen stress [aconitase and Complex I]). Mitochondrial function was altered in $Sod2^{-/+}$ mice, as shown by decreased respiration by complex I and increased sensitivity of PT to induction by calcium and *t*-butylhydroperoxide. Induction of PT in heart mitochondria from $Sod2^{-/+}$ mice was associated with release of cytochrome *c* and DNA fragmentation. Cardiomyocytes from neonatal $Sod2^{-/+}$ and $Sod2^{-/-}$ mice were more sensitive to death than cardiomyocytes from $Sod2^{+/+}$ mice after *t*-butylhydroperoxide treatment. Sensitivity was decreased by inhibiting PT with cyclosporin A.

To understand the role of MnSOD in antioxidant defense and apoptosis in the heart, Remmen examined reduced MnSOD expression on oxidative damage, mitochondrial function and oxidative stress-induced apoptosis in hearts of $Sod2^{-/+}$ mice. MnSOD regulated the mitochondrial pathway of apoptosis as well as antioxidant defense. There was no change in life table parameters.

Diverse genes have evolved to protect cells from macromolecular damage. One class includes structural and regulatory genes for scavenger enzymes (e.g., SOD 1, 2, 3 and catalase). G.M. Martin (personal communication) found evidence supporting the theory in mice. Independent lines of transgenic mice overexpressing a cDNA for human catalase directed to mitochondria had ~17% increases in maximum life spans. Transgenic mouse lines overexpressing human CAT in perioxisomes or nuclei did not show a significant extension in life span.

In a series of studies (236,237,28,29), effects of oral supplementation with acetyl-L-carnitine and alpha lipoic acid on the physiological and memory function of elderly mice were examined. The physical activity of elderly mice - and their performance in memory tests improved to nearly the level of young mice. Acetyl-Lcarnitine was hypothesized to increase mitochondrial energy production by affecting membrane function and alpha-lipoic acid to deal with increased production of ROS. Improvement in function was greater when both agents were administered than when each was administered independently.

Bluher *et al* (238) engineered mice to have the insulin receptor in adiocytes disabled. These were raised in an experiment with several other strains - all were fed *ad libitum* diets. Mice with the insulin receptor knocked out had an 18% higher mean and maximum life span even though they ate more food. Knockout mice were lean despite higher food consumption.

This study suggests the importance of hormonal factors in controlling metabolism and oxidative processes. IGF-1, insulin and GH have been studied in multiple species (239). As biological complexity increases, receptor complexity increases (e.g., from one insulin receptors in flies and worms to four in tetrapods). Metabolic functions and growth and development processes may separate, as suggested by results of the Baltimore longitudinal Study of Aging (240). This may be due to thyroid (T3) hormone which controls mitrochondrial function and mitrochondriogenesis under oxidative stress (241).

9. CONCLUSIONS

Numerous studies support the notion that mutations and oxidative damage to mtDNA (with associated decline in mitochondrial respiratory function) are important contributors to human aging. Many animal models provide insights into effects of oxidative damage to mitochondria in aging. Mitochondrial oxidative damage plays a major role in life span control in various systems. It is not clear if this represents an effect on pathology or is related to basic aging processes.

As the biological complexity of an organism increases, the competition of growth and reproductive processes with somatic cell maintenance for energy may be reduced (239). The caloric restriction model may not apply in the same way to humans as it does in simpler test systems (240). Respiratory function and longevity may simultaneously increase in humans as has been found in some test systems (241). The role of oxidative processes in human mitochondria may be more complex, with multiple inter-dependent tissue systems linked by hormonal systems (242) than in, at least, some test systems.

10. ACKNOWLEGEMENTS

This work was supported by the National Longterm Care Survey (NLTCS) grant (No.AG07198-15) from the National Institute on Aging.

11. REFERENCES

1. Harman D: Aging: a theory based on free radical and radiation chemistry. *J gerontol* 11, 298-300 (1956)

2. Stadtman E R: Protein oxidation and ageing. *Science* 257, 1220–1224 (1992)

3. Martin GM, Austad SN, Johnson TE: Genetic analysis of ageing: role of oxidative damage and environmental stresses. Review. *Nat Genet* 13 (1), 25-34 (1996)

4. Sohal RS, Weindruch R: Oxidative stress, caloric restriction, and aging: a review. *Science* 273 (5271), 59-63 (1996)

5. Wallace DC: Mitochondrial diseases in man and mouse: a review. *Science* 283 (5407), 1482-8 (1999)

6. Finkel T, Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Review. *Nature* 408 (6809), 239-47 (2000)

7. Sun J, Folk D, Bradley TJ, Tower J: Induced overexpression of mitochondrial Mn-superoxide dismutase extends the life span of adult Drosophila melanogaster. *Genetics*, 161 (2), 661-72 (2002)

8. Huang WC, Juang SW, Liu IM, Chi TC, Cheng JT: Changes of superoxide dismutase gene expression and activity in the brain of streptozotocin-induced diabetic rats. *Neurosci Lett* 275(1), 25-8 (1999)

9. Robert E Huie and P Neta: Chemistry of Reactive oxygen Species. In: Reactive Oxygen Species in biological systems. Eds: Daniel L Gilbert and Carol A Colton, Kluker, Academic/Plenum Publishers, New York, Boston, Dordrecht, London, Moscow 33-73 (1999)

10. Gutteridge JM, Halliwell B: Iron toxicity and oxygen radicals. Review. *Baillieres Clin Haematol* 2 (2), 195-256 (1989)

11. Halliwell B, Cross CE: Oxygen-derived species: their relation to human disease and environmental stress. Review. *Environ Health Perspect* 102, Suppl 10, 512 (1994)

12. Allen RC: Role of oxygen in phagocyte microbicidal action. Review. *Environ Health Perspect* 102, Suppl 10, 201-8 (1994)

13. Babior BM: Activation of the respiratory burst oxidase. Review. *Environ Health Perspect* 102, Suppl 10, 53-6 (1994) 14. Robert E. Huie and P Neta: Chemistry of reactive oxygen species. In: Reactive oxygen species in biological systems. Eds: Daniel L. Gilbert and Carol A.Colton, Kluwer Academic Publishers, Hingham, MA 02018-0358 U.S.A.; AZ Dordrecht, The Netherlands 33-63 (1999)

15. Kim JM, Araki S, Kim DJ, Park CB, Takasuka N, Baba-Toriyama H, Ota T, Nir Z, Khachik F, Shimidzu N, Tanaka Y, Osawa T, Uraji T, Murakoshi M, Nishino H, Tsuda H: Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation. *Carcinogenesis* 19 (1), 81-5 (1998)

16. Kondo K, Matsumoto A, Kurata H, Tanahashi H, Koda H, Amachi T, Itakura H: Inhibition of oxidation of low-density lipoprotein with red wine. *Lancet* 344 (8930), 1152 (1994)

17. Yokozawa T, Liu ZW, Dong E: A study of ginsenoside-Rd in a renal ischemia-reperfusion model. *Nephron* 78 (2), 201-6 (1998)

18. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. *N Engl J Med* 336 (17), 1216-22 (1997)

19. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames, BN: Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. *Proc Natl Acad Sci USA* 99 (4), 2356-61 (2002)

20. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 334 (18), 1150-5 (1996)

21. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers and asbestos. *N Engl J Med* 334, 1145-9 (1994)

22. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 334 (18), 1145-9 (1996)

23. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY,Yu Y, Liu BQ, Tangrea J, Sun YH, Liu FS, Fraumeni JF Jr., Zhang YH, Li B: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific

mortality in the general population. J Natl Cancer Inst 85 (18), 1483-92 (1993)

24. Boveris A and LE Costa: The mitochondrial production of oxygen Radicals and Cellular Aging. In: Understanding the process of aging: The roles of mitochondria, free radicals, and antioxidants. Eds: E Cadenas and L Packer Press, Marcel Dekker, Inc. NY. Basel 1-16 (1999)

25. Patel RP, T Cornwell, and VM Darley-Usmar: The biochemistry of nitric oxide and peroxynitrite: implications for Mitochonchondrial function. In: Understanding the process of aging: The roles of mitochondria, free radicals, and antioxidants. Eds: E Cadenas and L Packer, Marcel Dekker, Inc. NY. Basel 39-55 (1999)

26. Hei TK, Piao CQ, He ZY, Vannais D, Waldren CA: Chrysotile fiber is a strong mutagen in mammalian cells. *Cancer Res* 52 (22), 6305-9 (1992)

27. Gerschman R, Gilbert D, Nye SW, Dwyer P, Fenn WO: Oxygen poisoning and X-irradiation: a mechanism in common. *Science* 119, 623-26 (1954)

28. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, and Ames BN: Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R- α -lipoic acid. *PNAS* 99 (4), 2356-2361 (2002a)

29. Liu J, Killilea DW, and Ames BN: Age-associated mitochondrial oxidative decay: Improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R- α -lipoic acid. *PNAS* 99 (4), 1876-1881 (2002b)

30. Linnane AW, Degli Esposti M, Generowicz M, Luff AR, Nagley P: The universality of bioenergetic disease and amelioration with redox therapy. *Biochem Biophys Acta* 1271, 191–194 (1995)

31. Yakes FM, Van Houten B: Mitochondria DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. *Proc Natl Acad Sci USA* 94, 514–519 (1997)

32. Yan LJ, Sohal RS: Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. *Proc Natl Acad Sci USA* 95, 12896–12901 (1998)

33. Cortopassi GA and Wong A: Mitochondrial in organismal aging and degeneration. *Biochem Biophys Acta* 1410, 183–193 (1999)

34. Goodell S, Cortopassi G: Analysis of oxygen consumption and mitochondrial permeability with age in mice. *Mech Ageing Dev* 101 (3), 245-56 (1998)

35. Klimek J, Schaap AP, Kimura T: The relationship between NADPH-dependent lipid peroxidation and degradation of cytochrome P-450 in adrenal cortex mitochondria. Biochem Biophys Res Commun 110 (2), 559-66 (1983)

36. Rouach H, Clement M, Orfanelli MT, Janvier B, Nordmann J, Nordmann R: Hepatic lipid peroxidation and mitochondrial susceptibility to peroxidative attacks during ethanol inhalation and withdrawal. *Biochim Biophys Acta* 753 (3), 439-44 (1983)

37. Marcillat O, Zhang Y, and Davies KJ: Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. *Biochem J* 259 (1), 181-9 (1989)

38. Musci G, Bonaccorsi di Patti MC, Fagiolo U, Calabrese L: Age-related changes in human ceruloplasmin. Evidence for oxidative modifications. *J Biol Chem* 268 (18), 13388-95 (1993)

39. Carney J M, Starke-Reed P E, and Oliver C N: Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N- *tert* -butyl-a-phenylnitrone. *Proc Natl Acad Sci USA* 88, 3633–3636 (1991)

40. Forster M J, Dubey A, and Dawson K M: Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. *Proc Natl Acad Sci USA* 93, 4765–4769 (1996)

41. Head E, Liu J, Hagen TM, Muggenburg BA, Milgram NW, Ames BN, Cotman CW: Oxidative damage increases with age in a canine model of human brain aging. *J Neurochem* 82 (2), 375-81 (2002)

42. Khalil A., Jay-Gerin J. P. and Fulop T., Jr: Age-related increased susceptibility of high-density lipoproteins (HDL) to in vitro oxidation induced by c-radiolysis of water. *FEBS Lett* 435, 153–158 (1998)

43. Lowseth L.A., Gillett N. A., Gerlach R. F. and Muggenburg B. A.: The effects of aging on hematology and serum chemistry values in the beagle dog. *Vet Clin Pathol* 19, 13–19 (1990)

44. Ramsey J. J., Harper M. E. and Weindruch R.: Restriction of energy intake, energy expenditure, and aging. *Free Radic Bio. Med* 29, 946–968 (2000)

45. Packer L and Fuehr K: Low oxygen concentration extends the lifespan of cultured human diploid cells. *Nature* 267, 423–425 (1977)

46. Fraga CG, Shigenaga MK, Park JW, Degan P, and Ames BN: Oxidative damage to DNA during aging: 8-Hydroxy-2'-deoxyguanosine in rat organ DNA and urine. *Proc Natl Acad Sci USA* 87, 4533–4537 (1990)

47. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and

long-term induction of Cip1 in normal human fibroblasts. *Genes Dev* 8, 2540–2551 (1994)

48. Shay JW, Wright WE, Werbin H: Toward a molecular understanding of human breast cancer: A hypothesis. *Breast Cancer Res Treat* 25, 83–94 (1993)

49. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. *Cancer Res* 51, 6304–6311 (1991)

50. Hayflick, L. & Moorhead, PS.: The serial cultivation of human diploid cell strains. *Exp. Cell Res.* 25, 585–621 (1961)

51. Hayflick L: The limited *in vitro* lifetime of human diploid cell strains. *Exp Cell Res* 37, 614-636 (1965)

52. Balin AK, Goodman DB, Rasmussen H, Cristofalo VJ: The effect of oxygen and vitamin E on the lifespan of human diploid cells *in vitro*. *J Cell Biol* 74, 58–67 (1977)

53. Petersen S, Saretzki G, von Zglinicki T: Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. *Exp Cell Res* 239, 152–160 (1998)

54. Sohal RS, Weindruch R: Oxidative stress, caloric restriction, and aging: a review. *Science* 273 (5271), 59-63 (1996)

55. Gille J.J., Joeje H: Cell culture models for oxidative stress: superoxide and hydrogen peroxide versus normobaric hyperoxia. Review. *Mutat Res* 275 (3-6), 405-14 (1992)

56. Stadtman ER, Levine RL: Protein oxidation. Ann N Y Acad Sci 899, 191-208 (2000)

57. Brunk UT, Terman A. Lipofuscin: Mechanisms of agerelated accumulation and influence on cell function. *Free Radic Biol Med* 33, 611–619 (2002)

58. Sohal RS, Lass A, Yan LJ Kwong L: Mitochondrial generation of reactive oxygen species and oxidative damage during aging: roles of coenzyme Q and tocopherol. In: Understanding the process of aging, L. Packer, Editor, Marcel Dekker, Inc., New York 119–142 (1999)

59. Yan LJ, Sohal RS: Prevention of flight activity prolongs the life span of the housefly, *Musca domestica*, and attenuates the age-associated oxidative damage to specific mitochondrial proteins. *Free Radic. Biol. Med* 29, 1143-1150 (2000)

60. Van Remmen H, Richardson A.: Oxidative damage to mitochondria and aging. Review. *Exp Gerontol* 36 (7), 957-68 (2001)

61. Harman D: The biologic clock: the mitochondria? *J Am Geriatr Soc* 20 (4), 145-7 (1972)

62. Miquel J, Economos AC, Fleming J, Johnson JE Jr.: Mitochondrial role in cell aging. *Exp Gerontol* 15 (6), 575-91 (1980)

63. Sohal RS: Mitochondrial changes in the heart of Drosophila repleta, Wollaston with age. *Exp Gerontol* 5 (3), 213-6 (1970)

64. Wei YH, Ma YS, Lee HC, Lee CF, and Lu CY: Mitochondrial theory of aging matures--roles of mtDNA mutation and oxidative stress in human aging: a review. *Zhonghua Yi Xue Za Zhi* (Taipei) 64 (5), 259-70 (2001)

65. Liu J, Atamna H, Kuratsune H, Ames BN: Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. *Ann N Y Acad Sci* 959, 133-66 (2002c)

66. Anderson S, Bankier AT, Barrell BG, De Bruijn, MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG: Sequence and organization of the human mitochondrial genome. *Nature* 290, 457–465 (1981)

67. Toescu EC, Myronova N, Verkhratsky A: Age-related structural and functional changes of brain mitochondria: a review. *Cell Calcium* 28 (5-6), 329-38 (2000)

68. Nicholls DG, Ferguson S: Bioenergetics 2. Academic Press, London (1992)

69. Van Remmen H, Richardson A. Oxidative damage to mitochondria and aging. Review. *Exp Gerontol* 36 (7), 957-68 (2001)

70. Tyler D: The mitochondrion in health and disease. Cambridge, England, VCH Publishers (1992)

71. Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. *Physiol Rev* 59 (3), 527-605 (1979)

72. Shigenaga MK, Hagen TM, and Ames BN: Oxidative damage and mitochondrial decay in aging: a review. *Proc Natl Acad Sci USA* 91 (23), 10771-8 (1994)

73. Beckman KB, Ames BN: The free radical theory of aging matures: a review. *Physiol Rev*, 78 (2), 547-81 (1998)

74. Ozawa T: Oxidative damage and fragmentation of mitochondrial DNA in cellular apoptosis: a review. *Biosci Rep* 17 (3), 237-50 (1997)

75. Clayton DA: Transcription of the mammalian mitochondrial genome: a review. *Annu Rev Biochem* 53, 573-94 (1984)

76. Croteau DL, Bohr VA: Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells: a review. *J Biol Chem* 272 (41), 25409-12 (1997)

77. Dizdaroglu M: Chemical determination of free radicalinduced damage to DNA: a review. *Free Radic Biol Med* 10 (3-4), 225-42 (1991)

78. Bibb MJ, Van Etten RA, Wright CT, Walberg MW, and Clayton DA: Sequence and gene organization of mouse mitochondrial DNA. *Cell* 26 (2 Pt 2), 167-80 (1981)

79. DiMauro S, Andreu AL: Mutations in mtDNA: Are we scraping the bottom of the barrel ?: a review. *Brain Pathol* 10 (3), 431-41 (2000)

80. Cortopassi GA, Arnheim N: Detection of a specific mitochondrial DNA deletion in tissues of older humans. *Nucl Acid Res* 18, 6927–6933 (1990)

81. Ozawa T, Tanaka M, Ikebe S, Ohno K, Kondo T, Mizuno Y: Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. *Biochem Biophys Res Commun* 172, 483–489 (1990)

82. Corral-Debrinski M, Stepien G, Shoffner JM, Lott MT, Kanter K, Wallace DC: Hypoxemia is associated with mitochondrial DNA damage and gene induction. Implications for cardiac disease. *JAMA* 266, 1812–1816 (1991)

83. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, and Wallace DC: Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. *Nature Genet* 2, 324–329 (1992)

84. Zhang C, Baumer A, Maxwell RJ, Linnane AW, Nagley P: Multiple mitochondrial DNA deletions in an elderly human individual. *FEBS Lett* 297, 34–38 (1992)

85. Simonetti S, Chen X, DiMauro S, Schon EA: Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR. *Biochim Biophys Acta* 1180, 113–122 (1992)

86. Cooper JM, Mann VM, Schapira AH: Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. *J Neurol Sci* 113, 91–98 (1992)

87. Baumer A, Zhang C, Linnane AW, Nagley P: Agerelated human mtDNA deletions: a heterogeneous set of deletions arising at a single pair of directly repeated sequences. *Am J Hum Genet* 54, 618–630 (1994)

88. Melov S, Shoffner JM, Kaufman A, Wallace DC: Marked increase in the number and variety of mitochondrial DNA rearrangements in aging human skeletal muscle. *Nucleic Acid Res* 23, 4122–4126 (1995)

89. Munscher C, Rieger T, Muller-Hocker J, and Kadenbach B: The point mutation of mitochondrial DNA characteristic for MERRF disease is found also in healthy people of different ages. *FEBS Lett* 317, 27–30 (1993)

90. Khrapko K, Coller HA, Andre PC, Li XC, Hanekamp JS, Thilly WG: Mitochondrial mutational spectra in human cells and tissues. *Proc Natl Acad Sci U S A* 94 (25), 13798-803 (1997)

91. Wang Y, Michikawa Y, Mallidis C, Bai Y, Woodhouse L, Yarasheski KE, Miller CA, Askanas V, Engel WK, Bhasin S, Attardi G: Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. *Proc Natl Acad Sci U S A* 98 (7), 4022-7 (2001)

92. Hayakawa M, Sugiyama S, Hattori K, Takasawa M, and Ozawa T: Age-associated damage in mitochondrial DNA in human hearts. *Mol Cell Biochem* 119, 95–103 (1993)

93. Muscari C, Giaccari A, Stefanelli C, Viticchi C, Giordano E, Guarnieri C, Caldarera CM: Presence of a DNA-4236 bp deletion and 8-hydroxy-deoxyguanosine in mouse cardiac mitochondrial DNA during aging. *Aging* (*Milano*) 8 (6), 429-33 (1996)

94. Kaneko T, Tahara S, Matsuo M: Non-linear accumulation of 8-hydroxy-2'-deoxyguanosine, a marker of oxidized DNA damage, during aging. *Mutat Res* 316 (5-6), 277-85 (1996)

95. Souza-Pinto NC, Croteau DL, Hudson EK, Hansford RG, Bohr VA: Age-associated increase in 8-oxodeoxyguanosine glycosylase/AP lyase activity in rat mitochondria. *Nucleic Acids Res* 27 (8), 1935-42 (1999)

96. Wei YH, Lu CY, Lee HC, Pang CY, Ma YS: Oxidative damage and mutation to mitochondrial DNA and age-dependent decline of mitochondrial respiratory function. *Ann N Y Acad Sci.* 854, 155-70 (1998)

97. Muller-Hocker J: Cytochrome c oxidase deficient fibres in the limb muscle and diaphragm of man without muscular disease: an age-related alteration. *J Neurol Sci* 100, 14–21 (1990)

98. Brierley EJ, Johnson MA, James OFW, Turnbull DM: Effects of physical activity and age on mitochondrial function. *Q J Med* 89, 251–258 (1996)

99. Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G: Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. *Science* 286 (5440), 774-9 (1999)

100. Jazin EE, Cavelier L, Eriksson I, and Oreland L, Gyllensten U: Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. *Proc Natl Acad Sci USA* 93 (22), 12382-7 (1996)

101. Bendall KE, Macaulay VA, and Sykes BC: Variable levels of a heteroplasmic point mutation in individual hair roots. *Am J Hum Genet* 61 (6), 1303-8 (1997)

102. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B: Somatic mutations of the mitochondrial genome in human colorectal tumours. *Nat Genet* 20 (3), 291-3 (1998)

103. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D: Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. *Science* 287 (5460), 2017-9 (2000)

104. Trounce I., Byrne E., and Marzuki S: Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing *Lancet* 1, 637-639 (1989)

105. Boffoli D., Scacco S.C., Vergari R., Solarino G., Santacroce G., and Papa S: Decline with age of the respiratory chain activity in human skeletal muscle. *Biochimica et Biophysica Acta* 1226 (1) 73-82 (1994)

106. Yen T.C., Chen Y.S., King K.L., Yeh S.H., and Wei Y.H: Liver mitochondrial respiratory functions decline with age. *Biochemical and Biophysical Research Communications* 165, 944-1003 (1989)

107. Bowling A.C., Mutisya E.M., Walker L.C., Price D.L., Cork L.C., and Beal M.F: Age-dependent impairment of mitochondrial function in primate brain. *Journal of Neurochemistry* 60 (5) 1964-1967 (1993)

108. Muller-Hocker J., Schneiderbanger K., Stefani F.H., and Kadenbach B: Progressive loss of cytochrome c oxidase in the human extraocular muscles in ageing -- a cytochemical-immunohistochmeical study. *Mutation Research* 275, 115-124 (1992)

109. Muller-Hocker J., Seibel P., Schneiderbanger K., and Kadenbach B: Different in situ hybridization patterns of mitochondrial DNA in cytochrome c oxidase-deficient extraocular muscle fibres in the elderly. *Virchows Arch A, Pathological Anatomy and Histopathology* 422, 7-15 (1993)

110. Piko L., Hougham A.J., and Bullpitt K.J.: Studies of sequence heterogeneity of mitochondrial DNA from rat and mouse tissues: evidence for an increased frequency of deletions/additions with aging. *Mechanisms of Ageing and Development* 43, 279-293 (1988)

111. Linnane A.W., Marzuki S., Ozawa T., and Tanaka M.: Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. *Lancet* 1 (8639), 642-645 (1989)

112. Linnane A.W., Baumer A., Maxwell R.J., Preston H., Zhang C., and Marzuki S.: Mitochondrial gene mutation: the aging process and degenerative diseases. *Biochemistry International* 22 (6) 1067-1076 (1990)

113. Yen T.C., Pang C.Y., Hsieh R.H., Su C.H., King K.L., and Wei Y.H.: Age-dependent 6kb deletion in human liver mitochondrial DNA. *Biochemistry International* 26, 457-468 (1992)

114. Yen, T.C., King K.L., Lee H.C., Yeh S.H., and Wei Y.H.: Age-dependent increase of mitochondrial DNA

deletions together with lipid peroxides and superoxide dismutase in human liver mitochondria. *Free Radical Biology and Medicine* 16 (2), 207-214 (1994)

115. Arnheim N. and Cortopassi GL: Deleterious mitochondrial DNA mutations accumulate in aging human tissues. *Mutation Research* 275, 157-167 (1992)

116. Cortopassi G. and Arnheim N.: Accumulation of mitochondrial DNA mutation in normal aging brain and muscle. In: Mitochondrial DNA in Human Pathology. Editors: DiMauro S. and Wallace D.C. Raven Press, N.Y, 125-136 (1992a)

117. Cortopassi G.A., Shibata D., Soong N.W., and Arnheim N.: A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. *Proceedings of the National Academy of Sciences of the United States of America* 89 (16), 7370-7374 (1992b)

118. Mann V.M., Cooper J.M., and Schapira A.H.V.: Quantitation of a mitochondrial DNA deletion in Parkinson's disease. *FEBS Letters* 299 (3), 218-222 (1992)

119. Soong N.W., Hinton D.R., Cortopassi G., and Arnheim N.: Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. *Nature Genetics* 2, 318-323 (1992)

120. Sugiyama S., Hattori K., Hayakawa M., and Ozawa T.: Quantitative analysis of age-associated accumulation of mitochondrial DNA with deletion in human hearts. *Biochemical and Biophysical Research Communications* 180, 894-899 (1992)

121. Wei, Y.H.: Mitochondrial DNA alterations as ageingassociated molecular events. *Mutation Research* 275, 145-155 (1992)

122. Hamblet N.S. and Castora F.J.: Mitochondrial DNA deletion analysis: a comparison of PCR quantitative methods. *Biochemical and Biophysical Research Communications* 207 (2), 839-847 (1995)

123. Munscher C., Muller-Hocker J., and Kadenbach B.: Human aging is associated with various point mutations in tRNA genes of mitochondrial DNA. *Biological Chemistry Hoppe Seyler* 374, 1099-1104 (1993a)

124. Munscher C., Rieger T., Muller-Hocker J., and Kadenbach B.: The point mutation of mitochondrial DNA characteristic for MERRF disease is found also in healthy people of different ages. *FEBS Letters* 317, 27-30 (1993b)

125. Rieger T., Munscher C., Seibel P., Muller-Hocker J., and Kadenbach B.: Detection of small amounts of mutated mitochondrial DNA by allele-specific PCR (AS-PCR) *Methods Mol Cell Biol* 4, 121-127 (1993)

126. Zhang C., Linnane A.W., and Nagley P.: Occurrence of a particular base substitution (3243 A to G) in mitochondrial DNA of tissues of ageing humans.

Biochemical and Biophysical Research Communications 195 (2), 1104-1110 (1993)

127. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, and Wallace DC: Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. *Nature Genet* 2, 324–329 (1992)

128. Wallace D.C.: Diseases of the mitochondrial DNA. *Annual Review of Biochemistry* 61, 1175-1212 (1992a)

129. Wallace D.C.: Mitochondrial genetics: a paradigm for aging and degenerative diseases? *Science* 256, 628-632 (1992b)

130. Mroczek-Tonska K, Ratajska D, Guillot C, Sasiadek M, Ambroziak A, Lubos L, Bartnik E.: Heteroplasmy analysis in the Polish patients with 11778A mutation responsible for Leber hereditary optic neuropathy. *Acta Biochim Pol* 49 (1), 257-62 (2002)

131. Volz-Lingenhohl A, Solignac M, Sperlich D: Stable heteroplasmy for a large-scale deletion in the coding region of Drosophila subobscura mitochondrial DNA. *Proc Natl Acad Sci U S A* 89 (23), 1152832 (1992)

132. Shoubridge EA: Mitochondrial DNA diseases: histological and cellular studies: a review. *J Bioenerg Biomembr* 26 (3), 301-10 (1994)

133. Tokunaga M, Mita S, Murakami T, Kumamoto T, Uchino M, Nonaka I, Ando M: Single muscle fiber analysis of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). *Ann Neurol* 35 (4), 413-9 (1994)

134. Macmillan C, Lach B, Shoubridge EA: Variable distribution of mutant mitochondrial DNAs (tRNA(Leu[3243])) in tissues of symptomatic relatives with MELAS: the role of mitotic segregation. *Neurology* 43 (8) 1586-90 (1993)

135. Manfredi G, Vu T, Bonilla E, Schon EA, DiMauro S, Arnaudo E, Zhang L, Rowland LP, and Hirano M: Association of myopathy with large-scale mitochondrial DNA duplications and deletions: which is pathogenic? *Ann Neurol* 42 (2), 180-8 (1997)

136. Nakamura N, Hattori N, Tanaka M, Mizuno Y: Specific detection of deleted mitochondrial DNA by in situ hybridization using a chimera probe. *Biochim Biophys Acta* 1308 (3), 215-21 (1996)

137. Vu TH, Tanji K, Pallotti F, Golzi V, Hirano M, DiMauro S, Bonilla E: Analysis of mtDNA deletions in muscle by in situ hybridization. *Muscle Nerve* 23 (1), 80-5 (2000)

138. Engelhardt M, Martens UM: The implication of telomerase activity and telomere stability for replicative aging and cellular immortality (Review). *Oncol Rep* 5 (5), 1043-52 (1998)

139. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB: Telomere end-replication problem and cell aging. *J Mol Biol* 225 (4), 951-60 (1992)

140. Blackburn EH: Telomere states and cell fates. *Nature* 408 (6808), 53-6 (2000)

141. Proctor CJ, Kirkwood TB: Modelling telomere shortening and the role of oxidative stress. *Mech Ageing Dev* Feb 123 (4), 351-63 (2002)

142. Petersen S, Saretzki G, von Zglinicki T: Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. *Exp Cell Res* 239 (1), 152-60 (1998)

143. von Zglinicki T. Telomeres and replicative senescence: Is it only length that counts? Review. *Cancer Lett* 168 (2), 111-6 (2001)

144. von Zglinicki T: Oxidative stress shortens telomeres. *Trends Biochem Sci* 27 (7), 339-44 (2002)

145. Lemasters JJ, DiGuiseppi J, Nieminen AL, Herman B. Blebbing: free Ca2+ and mitochondrial membrane potential preceding cell death in hepatocytes. *Nature* 325 (6099), 78-81 (1987)

146. Hockenbery DM, Nunfez, G, Milliman, C, Schreiber, RD and Korsmeyer, SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 348, 334-336 (1990)

147. Pastorino JG, Snyder JW, Serroni A, Hoek JB and Farber JL: Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. *J. Biol. Chem* 268, 13791-13798 (1993)

148. Imberti R., Nieminen A.-L., Herman B. and Lemasters J.J.: Mitochondrial and glycolytic dysfunction in lethal injury to hepatocytes by t-butylhydroperoxide: protection by fructose, cyclosporin A and trifluoperazine. *J Pharmacol Exp Ther* 265, 392-400 (1993)

149. Ankarcrona M., Dypbukt J.M., Bonfoco E., Zhivotovsky B., Orrenius S., Lipton S.A. and Nicotera P: Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. *Neuron* 15, 961-973 (1995)

150. Zamzami N., Marchetti P., Castedo M., Decaudin D., Macho A., Hirsch T., Susin S.A., Petit P.X., Mignotte B. and Kroemer G: Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. *J Exp Med* 182, 367-377 (1995)

151. Liu X., Kim C.N., Yang J., Jemmerson R. and Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell* 86, 147-157 (1996)

152. Zou H., Henzel W.J., Liu X., Lutschg A., and Wang X.: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. *Cell* 90, 405-413 (1997)

153. Troen BR: The biology of aging: a review. *Mt Sinai J Med* 70 (1), 3-22 (2003)

154. Kroemer G, Dallaporta B, Resche-Rigon M: The mitochondrial death/life regulator in apoptosis and necrosis: a review. *Annu Rev Physiol* 60, 619-42 (1998)

155. Esteve JM, Mompo J, Garcia de la Asuncion J, Sastre J, Asensi M, Boix J, Vina JR, Vina J, Pallardo FV: Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis: studies in vivo and in vitro. *FASEB J* 13 (9), 1055-64 (1999)

156. Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B: The biochemistry of programmed cell death: a review. *FASEB J* 9 (13), 1277-87 (1995)

157. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. *Cell* 75 (2), 241-51 (1993)

158. Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M, Kroemer G: Mitochondrial control of nuclear apoptosis. *J Exp Med* 183 (4), 1533-44 (1996)

159. Skulachev VP. The programmed death phenomena, aging, and the Samurai law of biology. *Exp Gerontol* 36 (7), 995-1024. Review (2001)

160. Juan Sastre, Federico V. Pallardo, Jose Garcia de la Asuncion, Miguel A. Asensi, Juan M. Esteve, and Jose Vinaribes: Role of mitochondria in oxidative stress associated with aging and apoptosis: studies in intact cells. In: Understanding the process of aging, the role of mitochondria, free radicals, and antioxidants. Eds: E Cadenas and L Packer, Marcel Dekker Press, Inc. NY. Basel 181-202 (1999)

161. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. *Nature* 361 (6410), 365-9 (1993)

162. Jiang S, Cai J, Wallace DC, Jones DP: Cytochrome cmediated apoptosis in cells lacking mitochondrial DNA. Signaling pathway involving release and caspase 3 activation is conserved. *J Biol Chem* 274 (42), 29905-11 (1999)

163. Chomyn A, Attardi G: MtDNA mutations in aging and apoptosis. Review. *Biochem Biophys Res Commun* 304 (3), 519-29 (2003)

164. Ames BN, Shigenaga MK, Hagen TM: Mitochondrial decay in aging. *Biochem Biophys Acta* 1271, 165–170 (1995)

165. Kim SH, Fountoulakis M, Cairns N, Lubec G.: Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. *J Neural Transm Suppl* (61), 223-35 (2001)

166. de la Asuncion JG, Millan A, Pla R, Bruseghini L, Esteras A, Pallardo FV, Sastre J, Vina J: Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA. *FASEB J* 10 (2), 333 (1996)

167. Sohal RS: Role of oxidative stress and protein oxidation in the aging process: a review. *Free Radic Biol Med* 33 (1), 37-44 (2002)

168. Agarwal S and Sohal R.S.: DNA oxidative damage and life expectancy in houseflies. *Proc. Natl. Acad. Sci.* USA 91, 12332–12335 (1994)

169. Agarwal S and Sohal R.S.: Aging and protein oxidative damage. *Mech. Aging Develop.* 75, 11–19 (1994)

170. Sohal RS, Agarwal S, Dubey A, Orr WC: Protein oxidative damage is associated with life expectancy of houseflies. *Proc Natl Acad Sci USA* 90 (15), 7255-9 (1993)

171. Sohal RS: The free radical hypothesis of aging: an appraisal of the current status: a review. *Aging* (Milano) 5 (1), 3-17 (1993)

172. Weindruch R. and Sohal R.S.: Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. *N. Engl. J. Med.* 337, 986–994 (1997)

173. Stadtman E.R: Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences [published erratum appears in *Free Radic Biol Med* 10 (3-4), 249 (1991)]. *Free Radic. Biol. Med.* 9, 315–325 (1990)

174. Sohal RS, Mockett RJ, Orr WC: Mechanisms of aging: an appraisal of the oxidative stress hypothesis. Review. *Free Radic Biol Med* 33 (5), 575-86 (2002)

175. Wallace DC: Mitochondrial defects in neurodegenerative disease. Review. *Ment Retard Dev Disabil Res Rev* 7 (3), 158-66 (2001)

176. Butterfield D.A. and Stadtman E.R.: Protein oxidation processes in aging brain. *Adv. Cell Aging Gerontol* 2, 161-191 (1997)

177. Butterfield DA, Howard BJ, Yatin S, Allen KL, Carney JM: Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-alpha-phenylnitrone. *Proc Natl Acad Sci USA* 94 (2), 674-8 (1997)

178. Dean RT, Fu S, Stocker R, and Davies MJ: Biochemistry and pathology of radical-mediated protein oxidation: a review. *Biochem J* 324 Pt 1, 1-18 (1997)

179. Butterfield DA and Kanski J: Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins: a review. *Mech Ageing Dev* 122 (9), 945-62 (2001)

180. Markesbery W.R: Oxidative stress hypothesis in Alzheimer's disease: a review. *Free Radic Biol Med* 23 (1), 134-47 (1997)

181. Friede RI: Enzyme histochemical studies of senile plaques. *J Neuropathol Exp Neurol* 24, 477–491 (1965)

182. Mecocci P, MacGarvey U, and Beal MF: Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. *Ann Neurol* 36 (5), 747-51 (1994)

183. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B: An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. *J Neurochem* 68 (5), 2061-9 (1997)

184. Gabbita SP, Lovell MA, Markesbery WR: Increased nuclear DNA oxidation in the brain in Alzheimer's disease. *J Neurochem* 71 (5), 2034-40 (1998)

185. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, and Smith MA: RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. *J Neurosci* 19 (6), 1959-64 (1999)

186. de la Monte SM, Luong T, Neely TR, Robinson D, Wands JR.: Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. *Lab Invest* 80 (8), 1323-35 (2000)

187. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA: Mitochondrial abnormalities in Alzheimer's disease. *J Neurosci* 21 (9), 3017-23 (2001)

188. Smith C. D., Carney J. M., Starke-Reed P. E., Oliver C. N., Stadtman E.R., Floyd R. A. and Markesbery W.R.: Excess brainprotein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. *Proc Natl Acad Sci USA* 88, 10540-10543 (1991)

189. Markesbery W. R. and Lovell M. A.: Fourhydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. *Neurobiol Aging* 19, 33-36 (1998)

190. Mirra S. S., Heyman A., McKeel D., Sumi S. M., Crain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., van Belle G., and Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II, Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 41, 479-486 (1991)

191. Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K. and Muller-Hill B.: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature* 325, 733-736 (1987)

192. Gabuzda D., Busciglio J., Chen L. B., Matsudaira P. and Yankner B. A.: Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. *J Biol Chem* 269, 13623-13628 (1994)

193. Multhaup G.: Amyloid precursor protein, copper and Alzheimer's disease. *Biomed Pharmacother* 51, 105-111 (1997)

194. in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH.: Nonsteroidal Antiinflammatory Drugs and the risk of Alzheimer's Disease. *The New England Journal of Medicine* 245 (21), 1515-1521 (2001)

195. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Eikelenboom P.: Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. *Curr Drug Targets* 4 (6), 461-8 (2003)

196. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ.: Chronic parkinsonism secondary to intravenous injection of meperidine analogues. *Psych Res* 1, 249–254 (1979)

197. Langston JW, Ballard PA, Tetrud JW, Irwin I: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* 219, 979–980 (1983)

198. Chiba K, Trevor A, Castagnoli N Jr.: Metabolism of the neurotoxic tertiaryamine, MPTP by brain monoamine oxidase. *Biochem Biophys Res Comm* 120, 574–578 (1984)

199. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH: Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metaboliteNmethyl-4-phenylpyridine by dopamine neurons explains selective toxicity. *Proc Natl Acad Sci USA* 82, 2173–2177 (1985)

200. Ramsay RR, Salach JI, Singer TP. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP1) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD1 linked substrates by MPP1. *Biochem Biophys Res Comm* 134, 743–748 (1986)

201. Nicklas WJ, Vyas I, Heikkila RE: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Life Sci* 36, 2503–2508 (1985)

202. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ.: A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-

methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Proc Natl* Acad Sci USA 80, 4546–4550 (1983)

203. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricuarte GA: Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. *Ann Neurol* 20, 449–455 (1986)

204. Swerdlow RH, Parks JK, Pattee G, Parker WD Jr.Role of mitochondria in amyotrophic lateral sclerosis. Review. *Amyotroph Lateral Scler Other Motor Neuron Disord* 1 (3), 185-90 (2000)

205. Blin O, Desnuelle C, Rascol O, Borg M, Peyro Saint Paul H, Azulay JP, Bille F, Figarella D, Coulom F, Pellissier JF, Montastruc JL, Chatel M, Sterratrice G.: Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. *J Neurol Sci* 125, 95–101 (1993)

206. Di Monte DA, Harati Y, Jankovic J, Sandy MS, Jewell SA, Langston JW.: Muscle mitochondrial ATP production in progressive supranuclear palsy. *J Neurochem* 62, 1631–1634 (1994)

207. Albers DS, Augood SJ, Martin DM, Standaert DG, Vonsattel JP, Beal MF.: Evidence for oxidative stress in subthalamic nucleus in progressive supranuclear palsy. *J Neurochem* 73, 881-884 (1999)

208. Albers DS, Augood SJ, Park LC, Browne SE, Martin DM, Adamson J, Hutton M, Standaert DG, Vonsattel JP, Gibson GE, Beal MF.: Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. *J Neurochem* 74, 878–881 (2000)

209. Smith RA, Porteous CM, Gane AM, Murphy MP: Delivery of bioactive molecules to mitochondria in vivo. *Proc Natl Acad Sci USA* 11 (9), 5407-5412 (2003)

210. Seibel P, Trappe J, Villani G, Klopstock T, Papa S, Reichmann H: Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases. *Nucleic Acids Res* 23 (1), 10-7 (1995)

211. Chrzanowska-Lightowlers ZM, Lightowlers RN, and Turnbull DM: Gene therapy for mitochondrial DNA defects: is it possible? a review. *Gene Ther* 2 (5), 311-6 (1995)

212. Vestweber D, Schatz G: DNA-protein conjugates can enter mitochondria via the protein import pathway. *Nature* 338 (6211), 170-2 (1989)

213. Melov S, Ravenscroft J, Malik S, Gill MS, Walker DW, Clayton PE, Wallace DC, Malfroy B, Doctrow SR, Lithgow GJ: Extension of life-span with superoxide dismutase/catalase mimetics. *Science* 289 (5484), 1567-9 (2000)

214. Keaney M, Gems D: No increase in lifespan in Caenorhabditis elegans upon treatment with the superoxide

dismutase mimetic EUK-8. Free Radic Biol Med 34 (2), 277-82 (2003)

215. Tower J., Aging mechanisms in fruit flies. *Bioessays* 18, 799–807. (1996)

216 Tatar M: Transgenes in the analysis of life span and fitness. *Am Nat* 154 Suppl, S67-S81 (1999)

217. Sohal R.S., Mockett, R.J. and Orr, W.C.: Current issues concerning the role of oxidative stress in aging: a perspective. In: Results and Problems in Cell Differentiation. Editor: Hekimi, Springer, Berlin (2000)

218. Tower J., Transgenic methods for increasing Drosophila life span. Review. *Mech Ageing Dev* 118 (1-2), 1-14 (2000)

219. Orr WC, Sohal RS: Does overexpression of Cu,Zn-SOD extend life span in Drosophila melanogaster? *Exp Gerontol* 38 (3), 227-30 (2003)

220. Orr WC, Sohal RS: Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster. *Science* 263 (5150), 1128-30 (1994)

221. Orr WC, Sohal RS: Effects of Cu-Zn superoxide dismutase overexpression of life span and resistance to oxidative stress in transgenic Drosophila melanogaster. *Arch Biochem Biophys* 301 (1), 34-40 (1993)

222. Orr WC, Sohal RS: The effects of catala2se gene overexpression on life span and resistance to oxidative stress in transgenic Drosophila melanogaster. *Arch Biochem Biophys* 297 (1), 35-41 (1992)

223. Sun J, Tower J: FLP recombinase-mediated induction of Cu/Zn-superoxide dismutase transgene expression can extend the life span of adult Drosophila melanogaster flies. *Mol Cell Biol* 19 (1), 216-28 (1999)

224. Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, Boulianne GL: Extension of *Drosophila* lifespan by overexpression of human *SOD1* in motorneurons. *Nature Genet* 10, 171-175 (1998)

225. Amstad P, Peskin A, Shah G, Mirault ME, Moret R, Zbinden I, Cerutti P: The balance between Cu, Zn-superoxide dismutase and catalase affects the sensitivity of mouse epidermal cells to oxidative stress. *Biochemistry* 30, 9305-9313 (1991)

226. Riddle, D. L. & Alberts, P. S.: Genetic and environmental regulation of dauer larva development. In *C. elegans II* (eds Riddle, D. L., Blumenthal T., Meyer, B. J. & Priess, J. R.) 739-768 (Cold Spring Harbor Press, New York, (1997)

227. Kenyon, C: Environmental factors and gene activities that influence life span. In *C. elegans II*. Eds: Riddle, D. L.,

Blumenthal, T., Meyer, B. J. & Priess, J. R. Cold Spring Harbor Press, New York 791-814 (1997)

228. Taub J, Lau JF, Ma C, Hahn JH, Hoque R, Rothblatt J, Chalfie M: A cytosolic catalase is needed to extend adult lifespan in C. elegans daf-C and clk-1 mutants. *Nature* 399 (6732), 162-6 (1999). Taub J, Lau JF, Ma C, Hahn JH, Hoque R, Rothblatt J, Chalfie M. Retraction. *Nature* 421 (6924), 764 (2003)

229. Lakowski B, Hekimi S: The genetics of caloric restriction in Caenorhabditis elegans. *Proc Natl Acad Sci U S A* 95 (22), 13091-6 (1998)

230. Lakowski B, Hekimi S: Determination of life-span in Caenorhabditis elegans by four clock genes. *Science* 272 (5264), 1010-3 (1996)

231. Ahmed A, Tollefsbol T: Telomeres and telomerase: basic science implications for aging. Review. *J Am Geriatr Soc* 49 (8), 1105-9 (2001)

232. Lim CS, Mian IS, Dernburg AF, Campisi J: C. elegans clk-2, a gene that limits life span, encodes a telomere length regulator similar to yeast telomere binding protein Tel2p. *Curr Biol* 11 (21), 1706-10 (2001)

233. Benard C, McCright B, Zhang Y, Felkai S, Lakowski B, Hekimi S: The C. elegans maternal-effect gene clk-2 is essential for embryonic development, encodes a protein homologous to yeast Tel2p and affects telomere length. *Development* 128 (20), 4045-55 (2001)

234. Lee SS, Lee RY, Fraser AG, Kamath RS, Ahringer J, Ruvkun G: A systematic RNAi screen identifies a critical role for mitochondria in C. elegans longevity. *Nat Genet* 33 (1), 40-8 (2003)

235. Van Remmen H, Williams MD, Guo Z, Estlack L, Yang H, Carlson EJ, Epstein CJ, Huang TT, Richardson A: Knockout mice heterozygous for Sod2 show alterations in cardiac mitochondrial function and apoptosis. *Am J Physiol Heart Circ Physiol* 281 (3), H1422-32 (2001)

236. Walter PB, Knutson, MD, Paler-Martinez A, Lee S, Xu, Y, Viteri FE, and Ames BN: Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. *PNAS* 99 (4), 2264-2269 (2002)

237. Hagen, T.M., Liu, J., Lykkesfeldt, J., Wehr, C.M., Ingersoll, R.T., Vinarsky, V., Bartholomew, J.C., and Ames, B.N.: Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. *Proc Natl Acad Sci USA* 99 (4), 1870-1875 (2002)

238. Bluher M, Kahn BB, Kahn CR: Extended longevity in mice lacking the insulin receptor in adipose tissue. *Science* 299 (5606), 572-4 (2003)

Role of Oxidative Damage in Mitochondria during Aging

239. Tatar M, Bartke A, Antebi A: The endocrine regulation of aging by insulin-like signals. Review. *Science* 299 (5611), 1346-51 (2003)

240. Roth GS, Lane MA, Ingram DK, Mattison JA, Elahi D, Tobin JD, Muller D, Metter EJ: Biomarkers of caloric restriction may predict longevity in humans. *Science* 297 (5582), 811 (2002)

241. Wrutniak-Cabello, C., Casas F., and Cabello G: Thyroid hormone action in mitochondria. *J Mol Endocrinol* 26, 67-77 (2001)

242. Manton KG: Aging and Longevity of Human Population. *Encyclopoedia of Endocrine Diseases* Submitted (2003)

Key Words: Oxidative damage, Free radicals, Reactive oxygen species, ROS, Mitochondrial DNA, mtDNA, Aging, Review

Send correspondence to: Hai Huang, MD., Ph.D. Duke University, Center for Demographic Studies, 2117 Campus Drive Box 90408, Durham, NC 27708, Tel: 919-668-2717, Fax: 919-684-3861, E-mail: hhai@cds.duke.edu